Sugi Predict

Sugi Predict / Compounds / SCHEMBL1748635

SCHEMBL1748635

SCHEMBL1748635

CC(C)(C)OC(=O)N1CCC(Nc2nc(Cl)ncc2F)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.54
▸ ALDH1A1 P00352 2/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ GPR119 Q8TDV5 3/20 0.50
▸ CNR1 P21554 3/20 0.47
▸ CNR2 P34972 1/20 0.47
▸ NSD2 O96028 1/20 0.47
▸ CCNT1 O60563 1/20 0.47
▸ DNMT3A Q9Y6K1 1/20 0.46
▸ BTK Q06187 2/20 0.45
▸ EGFR P00533 1/20 0.45
▸ ALK Q9UM73 1/20 0.45
▸ JAK1 P23458 1/20 0.44
▸ EPHX1 P07099 1/20 0.44
▸ SYK P43405 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10007451 0.94 KMT2A (0.49) KMT2AALDH1A1NPC1MAPTMAPK1
SCHEMBL4001705 0.94 KMT2A (0.49) KMT2AALDH1A1NPC1MAPTMAPK1
SCHEMBL2127361 0.94 KMT2A (0.49) KMT2AALDH1A1NPC1MAPTMAPK1
SCHEMBL10303476 0.89 KMT2A (0.50) KMT2AALDH1A1NPC1MAPTMAPK1
SCHEMBL17196934 0.89 CNR1 (0.53) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL31059292 0.88 KMT2A (0.43) KMT2AALDH1A1NPC1MAPTMAPK1
SCHEMBL13859335 0.88 KMT2A (0.53) KMT2ABTKEGFR
SCHEMBL14672538 0.88 KMT2A (0.53) KMT2ABTKEGFR
SCHEMBL2128326 0.88 KMT2A (0.53) KMT2ABTKEGFR
SCHEMBL1782933 0.87 ALDH1A1 (0.51) ALDH1A1NPC1MAPTMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4617261-A1 2,4,5-TRISUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF Wenzhou Medical University (CN) 2025-09-17 — — EP disclosed
CN-115894381-B 2,4, 5-Trisubstituted pyrimidine compound and preparation method and application thereof 温州医科大学 2024-10-18 — — CN disclosed
US-20240270698-A2 NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2024-08-15 — — US disclosed
US-20230348399-A1 NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2023-11-02 — — US disclosed
US-20230348399-A1 NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2023-11-02 — — US disclosed
US-20230348399-A1 NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2023-11-02 — — US disclosed
CN-115894381-A 2,4,5-trisubstituted pyrimidine compound and preparation method and application thereof 温州医科大学 2023-04-04 — — CN disclosed
EP-4079726-A1 NOVEL PYRIMIDIN DERIVATIVE AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2022-10-26 — — EP disclosed
CN-114829344-A Novel pyrimidine derivative and use thereof 韩国化学研究院 2022-07-29 — — CN disclosed
US-7968568-B2 [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus HOFFMANN-LA ROCHE INC. (US) 2011-06-28 — — US disclosed
EP-2044054-B1 PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY HOFFMANN LA ROCHE (CH) 2011-06-08 — — EP disclosed
US-20100069413-A1 Pyrimidine and Quinazoline Derivatives CHRIST ANDREAS D 2010-03-18 — — US disclosed
US-7674804-B2 Pyrimidine and quinazoline derivatives as SST5 modulators HOFFMANN-LA ROCHE INC. (US) 2010-03-09 — — US disclosed
EP-2044054-A2 PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY F. Hoffmann-Roche AG (CH) 2009-04-08 — — EP disclosed
US-20080045550-A1 Pyrimidine and quinazoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 2008-02-21 — — US disclosed
WO-2008000692-A2 PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069413-A1 Pyrimidine and Quinazoline Derivatives SSTR5, SSTR3, NPY5R KMT2A 4536/4885ALDH1A1 2667/4885NPC1 2475/4885
US-20240270698-A2 NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF LRRK2, PFKL, PDK3 KMT2A 2642/4885ALDH1A1 2226/4885NPC1 1674/4885
US-20080045550-A1 Pyrimidine and quinazoline derivatives SSTR5, SSTR3, NPY5R KMT2A 4536/4885ALDH1A1 2667/4885NPC1 2475/4885
US-20230348399-A1 NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF LRRK2, PFKL, PDK3 KMT2A 2642/4885ALDH1A1 2226/4885NPC1 1674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.